Primary nephrotic syndrome in adults is characterized by severe proteinuria and hypoalbuminemia. This was the first clinical trial to test rituximab in adult-onset frequently relapsing nephrotic ...

Findings showed a greater proportion of patients achieved sustained complete remission with obinutuzumab vs mycophenolate mofetil at week 52. Topline data were announced from a phase 3 study ...

For children with nephrotic syndrome, there was no difference in time to relapse between two commonly used non-steroid immunosuppressive medications, according to an observational study that emulated ...

A groundbreaking study, presented today at the 61st ERA Congress, has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome. Using ...

In a trial, rituximab demonstrated clinical efficacy in reducing proteinuria in patients with FRNS or SDNS. Intravenous rituximab is safe and effective in patients with frequently relapsing nephrotic ...